Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of beta1 adrenergic receptors. Landiolol specifically blocks cardiac beta1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-alpha-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury[1][2][3].
Molekulargewicht:
509.59
CAS Nummer:
[133242-30-5]
Formel:
C25H39N3O8
Target-Kategorie:
Adrenergic Receptor,Calcium Channel,Potassium Channel,Reactive Oxygen Species (ROS)
Anwendungsbeschreibung:
Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
